Syndax Pharmaceuticals (SNDX) Receivables - Other (2015 - 2026)

Syndax Pharmaceuticals' Receivables - Other history runs 12 years deep, the most recent figure standing at $24.7 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 586.11% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (up 586.11% YoY), while the FY2025 annual figure was $28.1 million, up 2061.54% from the prior year.
• Receivables - Other was $24.7 million for Q1 2026 at Syndax Pharmaceuticals, up from $6.4 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $24.7 million in Q1 2026 to a low of $158000.0 in Q1 2022.
• Historically, Receivables - Other has averaged $5.1 million across 5 years, with a median of $1.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Receivables - Other sank 64.68% in 2023, then jumped 1666.69% in 2025.
• A 5-year view of Receivables - Other shows it stood at $3.5 million in 2022, then tumbled by 64.68% to $1.2 million in 2023, then jumped by 196.25% to $3.6 million in 2024, then surged by 76.18% to $6.4 million in 2025, then surged by 285.7% to $24.7 million in 2026.
• The last three Receivables - Other figures came in at $24.7 million (Q1 2026), $6.4 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.